Skip to content
Saturday, 21 November 2026
Inspire.News

Unveiling truth, one story at a time

Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?

Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
Image: The Motley Fool

The good news is that Bristol Myers Squibb's new drugs are growing; the bad news is that one old drug is nearing its patent expiration.

Full story

Continue reading this story on The Motley Fool, the publisher that reported it.

Read the full story at The Motley Fool ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

Topics in this story

More from Business

See all